Feb 23, 2024 — PassPort Technologies, Inc. (PPTI) initiated a US Phase 1 clinical study of Zolmitriptan PassPort® utilizing its proprietary transdermal microporation system, PassPort® platform technology, for the treatment of acute migraine. Besides the anticipated faster onset of action compared to the zolmitriptan oral tablet, the study evaluates the safety of the PassPort® System and its pharmacokinetics.
Dec 18, 2023 — In this collaborative research, PPTI and ARCT combine their ground-breaking technologies, the transdermal drug delivery technology PassPort® system and the lipid-mediated delivery technology LUNAR®, to provide new options for mRNA vaccines and therapeutics. LUNAR® technology is the enabling technology used in Kostaive™, the first self-amplifying mRNA COVID vaccine in the world approved in Japan on November 28, 2023.
June 5, 2023 — PassPort Technologies and IP Gaia have entered into a strategic business agreement designed to enhance business activities and build relationships with third parties around PassPort's transdermal platform technology and pipeline.
June 10, 2022 — PassPort Technologies was selected as one of the 'Top 10 Drug Delivery Solution Providers in 2022' by the leading print and digital publication Medical Tech Outlook. Their evaluation panel considered PassPort Technologies as a top innovative company that is at the forefront of providing drug delivery solutions and impacting the industry.
March 1, 2022 — Collaborative research with Japan's Josai University resulted in a March 2022 publication in the European Journal of Pharmaceutical Sciences. The journal article -- "Enhancement of skin permeation of fluorescein isothiocyanate-dextran 4 kDa (FD4) and insulin by thermalporation" -- utilized PassPort Technologies delivery platform to improve skin permeation of FD-4 and transdermal absorption of insulin.
October 15, 2020 — Professors Ouchi (Hamamatsu University) and Suzuki (Hokkaido University) were 2020 Catalyst Awardees of the Healthy Longevity Global Competition held by the U.S. National Academy of Medicine. The PassPort® System was an integral part of their research project titled: "Development of a Novel Alzheimer's Disease Treatment Method by a Unique Brain Protein-derived Peptide with an Advanced Transdermal Absorption Device".
May 14, 2020 -- Research of Professor Yukitoshi Nagahara will be conducted in collaboration with the Clinical Research, Innovation and Education Center at Tohoku University Hospital (CRIETO) in Japan
April 1, 2020 -- Expectations for early clinical application of revolutionary anticancer drugs from Tokyo University of Science using a novel delivery technology
November 18, 2019 -- PassPort Technologies was featured in a recent article published by Nikkei Business Daily. The interview was conducted with PassPort's COO, Dr. Hirotoshi Adachi -- 点滴や錠剤を「貼り薬OKに」 米企業が新投与技術
October 18, 2019 -- Expecting early clinical application of ground-breaking drug discovery innovation generated by Hokkaido University and administered by new drug delivery technology (PassPort® System)
October 1, 2019 -- PassPort Technologies and Axcelead Drug Discovery Partners:
July 1, 2019 -- Nitto Denko Corporation and the Drug Discovery Gateway Investment Limited Partnership operated by Whiz Partners Inc. entered an alliance to accelerate the commercialization of the PassPort® System, an innovative transdermal therapeutic system.